Menu Close ✕

About
Technology overview
- Technology overview
- Immunotherapy
Clinical Studies
Investors
Contact

Ultimovacs – Investors – ESG

ESG

ESG documents

ESG Guidelines
ESG Report 2023
ESG Report 2022

E-mail:

mail@ultimovacs.com ir@ultimovacs.com medinfo@ultimovacs.com

Phone number: +47 413 80 080

Ullernchausséen 64
0379 Oslo
Norway View in Google Maps

Technology

Technology
Clinical studies
Immunotherapy

Ultimovacs

About Ultimovacs
Team
Board of directors
Contact us

Investors

Share information
Financial reports
Investor relations contacts
News

Copyright © Ultimovacs ASA 2024 | Privacy statement